3D render of human kidney on science background: © Rasi – stock.adobe.com
A personalized cancer vaccine (PCV) demonstrated antitumor immunity and delayed recurrence in patients with advanced high-risk, fully resected clear cell renal cell carcinoma (RCC), according to results of a study from the Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard published in Nature.1
In the investigator-initiated phase I trial (NCT02950766), researchers found that at median follow-up of 40.2 months after surgery, none of the 9 participants had disease recurrence and no dose-limiting toxicities were observed. They observed T cell immune responses against the vaccine’s antigens, including those linked to common RCC driver mutations in VHL, PBRM1, BAP1, KDM5C and PIK3CA in all patients.
“The neoantigens targeted by…